UBS Group Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Equities researchers at UBS Group assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Thursday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $38.00 price target on the stock.

A number of other brokerages also recently issued reports on JSPR. HC Wainwright dropped their price objective on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. JMP Securities reissued a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday, January 6th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Finally, Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $64.44.

Jasper Therapeutics Stock Up 2.0 %

JSPR stock opened at $5.49 on Thursday. The firm has a market cap of $82.35 million, a price-to-earnings ratio of -1.16 and a beta of 2.11. The company’s fifty day simple moving average is $13.42 and its 200 day simple moving average is $17.70. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JSPR. BNP Paribas Financial Markets lifted its stake in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after buying an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter worth about $59,000. MetLife Investment Management LLC lifted its position in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in Jasper Therapeutics during the 4th quarter worth approximately $223,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.